Neurocrine (NBIX): Accounting Value per Share

NBIX (Neurocrine Biosciences) - company brandmark

Neurocrine Biosciences (NBIX) is strengthening its position through the success of Ingrezza and the patent protection of its R&D portfolio. GURU.Markets quotes form a book value per share chart, where 36.49 captures the current value of the indicator. Fundamentals rely on a monopoly in the treatment of dyskinesia and FDA trials. Stability is ensured by the non-cyclical demand for neuromedicines, which remains independent of economic crises.

NBIX Neurocrine Equity per Share (07/04/2022 - 10/30/2026)

Summary analytical data breakdowns for neurocrine.com (NBIX)

- stock price and consensus target price:
Stock Price Neurocrine Biosciences Inc|NBIX - Analyst Median Target
- stock exchange capitalization data:
Market Valuation Neurocrine Biosciences, Inc.|NBIX - Business Value
- balance sheet net asset value indicators:
Net Assets per Single Share Neurocrine Biosciences|NBIX - Accounting Capitalization|Market Capitalization to Book Value Ratio neurocrine.com|NBIX - Company Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Neurocrine Biosciences|NBIX - Long-Term Debt to Capital|Short-Term Debt to Equity Neurocrine Biosciences, Inc.|NBIX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Neurocrine Biosciences, Inc.|NBIX - Long-Term Debt|Company Short-Term Debt Neurocrine Biosciences|Quick Ratio neurocrine.com
- earnings and multiples data:
NBIX - Company Net Income
General company analysis:NBIX - Neurocrine Biosciences Inc
Flagship merchandise of Neurocrine Biosciences, Inc.

Neurocrine Biosciences (NBIX) develops neurological drugs through strategic partnerships and joint funding of clinical trials. This model is reflected in the calculation of net assets minus all liabilities per share. This metric determines the actual capital value available to shareholders upon business liquidation. Growth in this indicator confirms financial stability and the absence of hidden write-offs. By analyzing the current book value per share, an investor assesses the issuer's internal margin of safety.

Main competitors

Biogen Corp - Book Value per Share|Net Assets per Share Regencell Corp RGC|AXSM (Axsome Therapeutics) - Accounting Value per Share|Equity per Share ACAD|Net Assets per Single Share Xenon|Equity per Share VKTX (Viking Therapeutics Inc)|Book Value per Share SUPN|CPRX - Net Asset Value per Share|Denali Therapeutics - Accounting Value per Share|Book Value per Share harmonybiosciences.com HRMY|BHVN - Net Assets per Single Share|Accounting Value of a Share AMLX (Amylyx Pharmaceuticals Inc)|Trevi Pharma (TRVI) - Net Assets per Single Share|Net Asset Value per Share Praxis Corp (PRAX)|Net Assets per Single Share Anavex Life Sciences|Equity per Share CBLL (ceribell.com)|Book Value per Share PRTA|ALEC - Net Asset Value per Share|Annexon Inc. - Accounting Value per Share|Book Value per Share Omeros Corp OMER|NGNE - Net Assets per Single Share|Accounting Value of a Share ACIU (acimmune.com)|Voyager Therapeutics, Inc. (VYGR) - Net Assets per Single Share|Net Asset Value per Share Neumora (NMRA)|SCLX (Scilex Holding Co.) - Book Value per Share|Accounting Value per Share Tevogen Bio Inc. (TVGN)|Net Assets per Single Share Alpha Cognition (ACOG)|CGTX (Cognition Therapeutics Inc.) - Accounting Value of a Share|Book Value per Share IKT (Inhibikase Therapeutics, Inc.)|Net Assets per Share Cassava Sciences Inc (SAVA)|ASRT - Net Assets per Single Share|COYA (Coya Therapeutics, Inc.) - Equity per Share|VTGN: Book Value per Share|Net Asset Value per Share Ovid Therapeutics (OVID)|Accounting Value per Share ABOS|CRVO: Accounting Value of a Share|Book Value per Share ATHE|Net Assets per Single Share CLNN (clene.com)|Book Value per Share PEPG (PepGen)|Net Assets per Share Jupiter Neurosciences, Inc. (JUNS)|RLMD - Net Assets per Single Share|Net Asset Value per Share Annovis Bio Inc|gracetx.com (GRCE) - Net Assets per Single Share|AIFF - Net Assets per Share|KLTO (ANEW Medical) - Book Value per Share|Accounting Value per Share NeuroSense Therapeutics, Ltd. (NRSN)|Book Value per Share RVPH|Net Assets per Share metaviatx.com|Book Value per Share NRXS (NeurAxis, Inc)|Helius Medical Technologies, Inc. (HSDT) - Net Asset Value per Share|PASG - Net Assets per Single Share|NEUP (Neuphoria Therapeutics Inc.) - Equity per Share|NERV: Book Value per Share|Accounting Value per Share Athira Pharma Inc|ADXN (Addex Therapeutics, Ltd.) - Book Value per Share|Net Asset Value per Share Alzamend ALZN|Net Assets per Single Share Cyclerion Therapeutics (CYCN)|Net Assets per Share protagenic.com|Net Assets per Single Share Pasithea Therapeutics Corp. KTTA|CRGT: Equity per Share|Avenue Therapeutics, Inc - Book Value per Share|BCLI: Net Assets per Single Share|CARA: Book Value per Share|CHRO - Net Assets per Share|Accounting Value per Share ELYM|Equity per Share ITCI (Intra-Cellular)|Net Assets per Single Share Longboard Pharma (LBPH)|Marinus Pharma - Equity per Share|Book Value per Share NKGN (NKGen Biotech, Inc.)|neurobopharma.com (NRBO) - Net Asset Value per Share|SAGE: Accounting Value per Share|SNPX - Book Value per Share|Trevena, Inc (TRVN) - Net Assets per Single Share|Vigil Neuroscience, Inc. - Accounting Value of a Share|Net Assets per Single Share Anew Medical|Net Asset Value per Share cerevel.com CERE